TriangleAtezolizumab (NCT06254911)
Atezolizumab trial for Oropharynx Cancer, Stage I (NCT06254911). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with resectable, p16-positive HPV-related oropharyngeal squamous-cell cancer, stage one with T1–T2 and N1 disease. Extensive or fixed lymph-node disease and prior checkpoint treatment exclude participation.
The idea: atezolizumab blocks PD-L1, a signal that restrains immune attack. Patients receive two intravenous doses before surgery through the mouth and neck-node removal. Researchers assess safety, treatment response, immune changes, and two-year event-free survival. Further treatment follows surgical pathology findings.
This phase 2 study plans 20 patients. Nabil Saba leads at Emory in Atlanta, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.